WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“Great Elm”), (NASDAQ: GEG), today announced plans to release financial results for the fiscal quarter ended September 30, 2023, after the close of market trading on Wednesday, November 8, 2023.
Company to Host Conference Call & Webcast
Great Elm will also host a conference call and webcast on Thursday, November 9, 2023, at 8:30 a.m. Eastern Time to discuss its fiscal 2024 first quarter financial results.
All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked.
A copy of the slide presentation that will be referenced during the conference call, can be found here.
The conference call will be webcast simultaneously and can be accessed here.
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.91 |
| Daily Change: | 0.01 0.53 |
| Daily Volume: | 16,823 |
| Market Cap: | US$55.870M |
February 05, 2025 November 11, 2024 February 13, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
